Bristol-Myers Squibb BMY Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $48.19B-0.2% | $48.3B+7.3% | $45.01B-2.5% | $46.16B-0.5% | ||
| $13.94B-0.2% | $13.97B+30.6% | $10.69B+5.5% | $10.14B+2.0% | ||
| $34.26B-0.2% | $34.33B+0.1% | $34.31B-4.7% | $36.02B-1.2% | ||
| 71.1%0.0pp | 71.1%-5.2pp | 76.2%-1.8pp | 78%-0.5pp | ||
| $9.95B-10.8% | $11.16B+20.0% | $9.3B-2.2% | $9.51B-6.7% | ||
| $7.27B-13.6% | $8.41B+8.3% | $7.77B-0.5% | $7.81B+1.6% | ||
| $38.87B-31.4% | $56.68B+55.0% | $36.57B-4.9% | $38.45B+0.4% | ||
| $9.33B+209% | -$8.55B-201% | $8.44B+9.4% | $7.71B-4.8% | ||
| $2.27B+310% | $554M— | —— | —— | ||
| $7.05B+178% | -$9.02B-212% | $8.03B+26.8% | $6.33B-9.5% | ||
| 14.6%+33.3pp | -18.7%-36.5pp | 17.8%+4.1pp | 13.7%-1.4pp | ||
| $3.45+177% | -$4.46-216% | $3.86+30.8% | $2.95-5.4% | ||
| $13.34B+1,175% | $1.05B-94.3% | $18.2B+1.2% | $17.99B-4.2% | ||
| 27.7%+25.5pp | 2.2%-38.3pp | 40.4%+1.5pp | 39%-1.5pp | ||
| $9.33B+209% | -$8.55B-201% | $8.44B+9.4% | $7.71B-4.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Bristol-Myers Squibb's revenue?
- Bristol-Myers Squibb (BMY) generated $48.5B in revenue over the trailing twelve months, up 1.8% year over year.
- Is Bristol-Myers Squibb profitable?
- Bristol-Myers Squibb reported $7.3B in net income over the trailing twelve months, a 15.0% net margin.
- What is Bristol-Myers Squibb's earnings per share?
- Bristol-Myers Squibb's diluted EPS over the trailing twelve months is $3.56.
- Where does Bristol-Myers Squibb's income statement data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
